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ABSTRACT 1 
In humans, the three main circulating monocyte subsets are defined by their relative cell 2 
surface expression of CD14 and CD16. They are all challenging to study because their 3 
characteristics are strongly context specific and this has led to a range of conflicting reports 4 
about their function, which is especially so for CD14
++
CD16
+
 (intermediate) monocytes. Ex 5 
vivo cultures are also often confounded by the concomitant use of immunosuppressive drugs. 6 
We therefore sought to characterize the phenotype and function of intermediate monocytes in 7 
the setting of acute inflammation prior to treatment in a cohort of 41 patients with acute 8 
alcoholic hepatitis (AH).  9 
 10 
Circulating intermediate monocytes were enriched in patients with AH and had an activated 11 
phenotype with enhanced expression of CCR2 and CD206 compared to healthy controls. Pro-12 
inflammatory cytokine expression, including IL-1β and IL-23, was also higher than in 13 
healthy controls, but both classical (CD14
++
CD16
-
) and intermediate monocytes in AH were 14 
refractory to TLR stimulation. Compared to healthy controls both AH monocyte subsets had 15 
greater phagocytic capacity, enhanced ability to drive memory T cell proliferation in co-16 
culture and skewed CD4
+
 T cells to express an increased ratio of IL-17:IFNγ.  Furthermore, 17 
liver tissue from AH patients demonstrated an enrichment of monocytes including the 18 
intermediate subset compared to controls. These data demonstrate that intermediate 19 
monocytes are expanded, functionally activated, induce CD4
+
 T cell IL-17 expression and are 20 
enriched in the liver of patients with AH. 21 
 22 
Words: 231  23 
 24 
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KEY POINTS 25 
Circulating intermediate monocytes are enriched in alcoholic hepatitis (AH) patients. 26 
AH intermediate monocytes are functionally activated. 27 
AH intermediate monocytes induce CD4
+
 T cell IL-17 and are enriched in the liver. 28 
  29 
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 INTRODUCTION 30 
 31 
Monocytes consist of a heterogeneous group of myeloid cells with varied function and 32 
phenotype. Although they are precursors of tissue resident macrophages and dendritic cells 33 
they are also effector cells in their own right (1). Accordingly, they are mobilized from the 34 
bone marrow in response to acute inflammatory states such as severe sepsis (2) and play an 35 
integral role in responding to pathogen and damage-associated molecular patterns (PAMPs 36 
and DAMPs) and shaping CD4
+
 T cell responses (3, 4). In humans, they are classified on the 37 
basis of their cell surface expression of CD14 (lipopolysaccharide [LPS] co-receptor) and 38 
CD16 (activatory Fc gamma receptor) into classical (CD14
++
CD16
-
), intermediate 39 
(CD14
++
CD16
+
) and non-classical (CD14
+
CD16
++
) subsets (5), each of which is thought to 40 
have distinct functions. Currently, the conventional view is that the dominant CD16
-
 classical 41 
subset egress from the bone marrow and are recruited to sites of inflammation where they act 42 
as phagocytes and give rise to patrolling pro-inflammatory CD16
++ 
cells, with the 43 
intermediate monocytes representing a transitional group between these two states (6).  44 
 45 
Consistent with this it is known that the CD14
++
CD16
+
 intermediate subset is enriched in the 46 
peripheral blood of patients with autoimmune conditions including rheumatoid arthritis (7). 47 
The role of these intermediate monocytes is however poorly understood, and we therefore 48 
sought to interrogate their function in the context of acute inflammation. To achieve this we 49 
recruited patients with acute alcoholic hepatitis (AH) as, at its onset, it is an exemplar disease 50 
for rapid-onset, severe systemic inflammation. Unlike chronic autoimmune diseases, on 51 
presentation it is typically not confounded by concomitant use of immunosuppressive 52 
medications such as glucocorticoids (8).  53 
  54 
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Although it is known that immune activation occurs concurrently with an impaired 55 
antimicrobial response in AH (9), and tissue resident hepatic macrophages (Kupffer cells) 56 
play an important role in orchestrating the immune mediators of hepatocyte damage (10, 11), 57 
little is known about the functional role of monocytes. Nonetheless, alcohol may activate 58 
them indirectly by modulating intestinal permeability as a consequence of intestinal dysbiosis 59 
(10), resulting in an increased exposure of circulating monocytes to PAMPS such as LPS 60 
(11).  In this study, we therefore hypothesized that circulating monocytes in the peripheral 61 
blood of patients presenting with acute AH would be expanded, phenotypically and 62 
functionally pro-inflammatory, in particular with regard to their influence on CD4
+
 T cells. 63 
  64 
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MATERIALS AND METHODS 65 
 66 
Participants 67 
Regulatory approval for this study was obtained from the UK’s National Health Service 68 
(NHS) Health Research Authority (07/Q2007/05 and 15/LO/1501) and it was conducted 69 
according to the International Council for Harmonization Good Clinical Practice Guidance 70 
and the Declaration of Helsinki. Written informed consent was obtained from all study 71 
participants.  72 
 73 
Patients admitted to University Hospitals Bristol NHS Foundation Trust (UHBristol) and 74 
University Hospitals Plymouth NHS Trust with a diagnosis of severe AH were prospectively 75 
recruited. Severe AH was defined in accordance with recently published trial standards (12) 76 
as recent onset jaundice (within previous 3 months) with a serum bilirubin level > 80 µmol/L 77 
in a heavy alcohol drinker (more than 60 (males) or 40 (females) g alcohol per day for more 78 
than 6 months) with aspartate aminotransferase / alanine aminotransferase > 1.5 and 79 
discriminant function > 32 (13). Peripheral blood was drawn prior to commencement of any 80 
medical therapy. Clinical and biochemical data were recorded, and survival was determined 81 
at day 90.  82 
 83 
Control blood samples were obtained both from healthy volunteers (HVs) and age and sex-84 
matched patients with alcohol related liver disease (ALD) in the absence of systemic liver 85 
inflammation. Patients with ALD were defined as heavy alcohol consumers (> 60 (males) or 86 
> 40 (females) g/alcohol per day for more than 6 months) with a diagnosis of cirrhosis 87 
(confirmed on imaging or histology) without severe AH (bilirubin < 80 µmol/L and 88 
discriminant function < 32) who had an unplanned hospital admission. Patients with ALD 89 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
us
e.
7 
 
received usual clinical care. The ALD control group was selected as these patients had many 90 
similar characteristics to the AH group (demographics, alcohol consumption, underlying liver 91 
disease and unplanned hospital admission). The key difference was the absence of the acute 92 
inflammatory state of AH. HVs were recruited from local laboratory and hospital workers 93 
who provided a self-declaration that they did not have any chronic health problems. Both 94 
ALD and HV donors gave a single sample of peripheral blood.  95 
 96 
An historic cohort of AH patients recruited at UHBristol between 2007 and 2010, underwent 97 
transjugular liver biopsy and tissue surplus to diagnostic requirement was used for this study. 98 
The median time of the biopsy after clinical diagnosis of AH was 9 days (range -1 to 143 99 
days). Only samples taken within 10 days of diagnosis were included in this study. In ALD 100 
patients who also underwent liver biopsy for clinical reasons (n=4) surplus tissue was used 101 
for this study. 102 
 103 
Peripheral blood mononuclear cell (PBMC) isolation and magnetic activated cell sorting 104 
PBMCs were isolated from whole blood by density gradient centrifugation using Ficoll-105 
Paque PLUS (GE Healthcare, Cardiff, UK). Autologous CD4
+
CD45RO
+
 memory T cells and 106 
monocytes were isolated from PBMCs using a memory CD4
+
 T cell isolation kit (Miltenyi 107 
Biotec Ltd, Surrey, UK) and a pan-monocyte negative selection kit (Miltenyi), respectively, 108 
according to the manufacturer’s instructions. Classical (CD16-) and intermediate (CD16+) 109 
monocyte subsets were subsequently separated using CD16 microbeads (Miltenyi).   110 
 111 
 112 
 113 
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Cell sorting by flow cytometry  114 
Flow cytometry was performed using the BD Influx flow cytometer (BD Biosciences, 115 
Oxford, UK) based on cell surface expression of CD3, CD4, CD45RO (memory CD4
+
 T 116 
cells) and HLA-DR, CD14 and CD16 (monocyte subsets, CD14
++
CD16
-
, CD14
++
CD16
+
 and 117 
CD14
+
CD16
++
). Dead cells were excluded using 7-aminoactinomycin D (7AAD; Thermo 118 
Fisher Scientific, Loughborough, UK). Monocytes were classified into three subsets 119 
according to the recommendations of an expert consensus panel based on CD14 and CD16 120 
expression (5). The gating strategy was performed according to a previously published report, 121 
which demonstrated accurate classification of monocytes in patients with acute liver disease 122 
(14) and is shown in Supplementary Figure 1A.  Purity of sorted cell populations was 123 
assessed by flow cytometry and was > 95% (data not shown). Details of antibodies are found 124 
in Supplementary Table I. 125 
 126 
Cell characterization by flow cytometry 127 
PBMCs were incubated with antibodies to CD3, CD4, CD14, CD16, CCR2, CCR5, CX3CR1, 128 
HLA-DR, CD206 and CD80 then washed and analyzed on a BD LSR II flow cytometer (BD 129 
Biosciences). Gating was performed using ‘fluorescence minus one’ controls for each 130 
fluorochrome. Details of antibodies are found in Supplementary Table I. Monocyte subsets 131 
were gated as per the sort strategy but without CD45RO (Supplementary Figure 1A). 132 
 133 
Monocyte subsets sorted by flow cytometry were cultured at 0.5 x 10
6
 / ml in complete media 134 
(RPMI supplemented with 10% fetal bovine serum [GE Healthcare], L-glutamine [Sigma-135 
Aldrich, Poole, UK] and penicillin/streptomycin [Sigma-Aldrich]) in the presence or absence 136 
of 100 pg/ml LPS (Sigma-Aldrich) for 18-24h with the addition of 1 µg/ml BD GolgiPlug 137 
(BD Biosciences) in a 37°C, 5% CO2 humidified incubator. Cells were permeabilized and 138 
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intracellular staining was performed with antibodies to IL-1β, IL-6, IL-8, IL-12p40, IL-23p19 139 
and TNFα. Gating was performed using ‘fluorescence minus one’ controls for each 140 
fluorochrome. Similar replicates were performed for other TLR ligands: peptidoglycan 141 
(TLR2/1) at 1 µg/ml, polyinosinic-polycytidylic (PI:C; TLR3) at 5 µg/ml) and Resiquimod 142 
(R848; TLR7/8) at 2.5 µg/ml (all TLR ligands from Invivogen, San Diego, USA). To assess 143 
whether endogenous stimuli affected cytokine expression, further replicates of monocyte 144 
subsets were stimulated with 200 ng/ml interferon alpha (IFNα; Biolegend, San Diego, USA) 145 
using an identical protocol. 146 
 147 
Phagocytosis assay 148 
Monocytes isolated by MACS were cultured at 0.5 x 10
6
 / ml with 1 ng/ml LPS (Sigma-149 
Aldrich) and 1 x 10
8
 fluorescently labelled microparticles (Park Scientific, Northampton, 150 
UK) for 10 minutes under tissue culture conditions. Cells were washed and stained with 151 
antibodies to CD14 and CD16 before fixation. Phagocytosis of fluorescent microparticles was 152 
quantified in each monocyte subset by flow cytometry (Figure 3A) (15). 153 
 154 
Monocyte and T cell co-culture assay 155 
Carboxyfluorescein succinimidyl ester (CFSE; Thermo Fisher Scientific) labelled T cells and 156 
unlabeled monocyte subsets were co-cultured in complete media at a ratio of 5:1 (1x10
5
 T 157 
cells: 2x10
4
 monocytes) for 5 days under tissue culture conditions, in wells pre-coated for 4hr 158 
at 37⁰C with 1 μg/ml anti-CD3 (Thermo Fisher Scientific).  A control well without 159 
monocytes but containing both anti-CD3 and anti-CD28 (both 1μg/ml; Thermo Fisher 160 
Scientific) was also included. For the final 4 hours of culture, cells were pulsed with 20ng/ml 161 
phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich), 1μM ionomycin (Sigma-Aldrich) 162 
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and 1 µg/ml BD GolgiStop (BD Biosciences).  Cells were assessed for intracellular cytokine 163 
expression (IL-17A and IFNγ) using flow cytometry (BD LSR II). 164 
 165 
Genetic analysis 166 
RNA was prepared from RNA stabilized samples (RNA protect, Qiagen, Manchester, UK) 167 
using the RNeasy plus micro kit (Qiagen). RNA was extracted from classical and 168 
intermediate monocytes isolated by cell sorting from 3 AH and HV subjects. RNA yields 169 
were determined by Nanodrop measurement (A260, Thermo Fisher Scientifc) and RNA 170 
integrity was assessed by RNA electrophoresis (Bioanalyser 2100, Agilent, Stockport, UK). 171 
Gene expression analysis was carried out using nCounter Human Immunology V2 code set 172 
(Nanostring technologies, Seattle, WA, USA). Quality control assessment and normalisation 173 
of Nanostring® reporter code counts (RCC) were performed following manufacturer 174 
recommended methods using nSolver™ Analysis Software version 4 (Nanostring 175 
technologies). Heatmaps were generated for the most differentially expressed genes for each 176 
monocyte subset for HV vs AH.  177 
 178 
Sample workflow 179 
In all participants, PBMCs were isolated and characterized by CD3, CD4, CD14 and CD16 180 
expression. In a pre-specified analysis, the first 14 HV and AH samples obtained underwent 181 
the full surface marker phenotype panel. The subsequent 10 AH patients were analyzed for 182 
phagocytosis. Cell sorting experiments required 150 mL fresh blood from each participant. 183 
Due to the volume required, we pre-specified an analysis of 10 unselected AH patients. 184 
 185 
 186 
 187 
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Liver tissue immunostaining 188 
Pathology specimens were acquired from 7 AH and 4 ALD patients who had undergone 189 
transjugular liver biopsy performed by an interventional radiologist at UHBristol.  5 µm 190 
sections of the formalin fixed and paraffin embedded tissues samples were obtained using a 191 
microtome and mounted onto slides. Samples were deparaffinised in Xylene (Sigma-Aldrich) 192 
and rehydrated in ethanol before antigen retrieval in 10 mM citrate buffer and incubating with 193 
primary antibodies to CD14 and CD16 (both Abcam, Cambridge, UK) overnight at 4°C. 194 
Bound antibodies were detected using fluorescently-labelled secondary antibodies (Abcam), 195 
mounted with DAPI (Vector Labs, Peterborough, UK) and fluorescence was visualized under 196 
confocal microscopy. Semi-quantitative analysis was performed by manual counting of 197 
fluorescent cells per x20 power field in 3 separate portal and lobule regions each. Mean cell 198 
counts per field were compared. 199 
 200 
Statistical analysis 201 
Continuous variables were compared using Mann-Whitney U tests for independent samples 202 
or Wilcoxon signed rank tests for paired samples. Categorical variables were compared using 203 
Fisher exact test. All analysis was performed using SPSS version 21 (IBM, New York, USA). 204 
Multiparametric cytokine expression was analyzed using SPICE v6.0 (freely available from 205 
http://exon.niaid.nih.gov/spice/).  206 
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RESULTS 207 
 208 
Peripheral blood analyses were conducted on 41 patients with severe AH (mean age 50.2 209 
years, 52% female). Mean disease severity scores of discriminant function (DF) and model 210 
for end-stage liver disease (MELD) were 60.8 (standard deviation [sd] 23.9) and 18.1 (sd 6.6) 211 
respectively. Overall, there was 14% and 24% 28- and 90-day mortality respectively. Age, 212 
gender, disease severity and outcome were similar in 10 patients with ALD who had mean 213 
age of 51.8 years, 50% female and MELD 15.1 (sd 5.4). There was 10% and 30% 28- and 90-214 
day mortality respectively (Table 1). Peripheral blood analyses were also performed on 47 215 
HVs.  216 
 217 
Intermediate monocytes are enriched in patients with AH 218 
Baseline total monocyte count was significantly greater than the healthy population median 219 
(0.71 v 0.60; p<0.01; Figure 1A). The proportion of peripheral blood intermediate 220 
monocytes, as measured by flow cytometry (Figure 1B) was significantly higher in patients 221 
with AH compared to HVs (16.7% v 7.4%; p<0.001; Figure 1C). Compared to HVs there is a 222 
commensurate reduction in the proportion of classical monocytes (78.4% v 83.0%; p<0.01; 223 
Figure 1C) and almost an absence in non-classical monocytes in patients with AH compared 224 
with HVs (0.7% v 3.9%; p<0.001; Figure 1C). The proportions of circulating monocyte 225 
subsets in patients with AH were also significantly different to those in patients with ALD 226 
(Figure 1C). Classical and intermediate proportions in ALD patients did not differ from HVs 227 
(Figure 1C). 228 
 229 
 230 
 231 
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Monocyte surface marker phenotype is altered in AH 232 
Flow cytometry was used to quantify surface marker phenotype in AH patients compared to 233 
HVs (Figure 1D). Intermediate monocytes from AH patients were phenotypically altered 234 
compared to HVs with higher expression of CCR2 (0.6 v 0.3 [expression normalized to HV 235 
classical monocytes]; p<0.01) and CD206 (3.4 v 1.2; p<0.01) and lower expression of HLA-236 
DR (1.8 v 4.9; p<0.001). In AH patients, intermediate monocytes expressed lower CCR2 (0.6 237 
v 1.0; p<0.05) but higher HLA-DR (1.8 v 0.5; p<0.001), CD206 (2.8 v 1.8; p<0.05) and 238 
CD80 (1.5 v 1.1; p<0.05) compared to classical monocytes. Although a small population, 239 
non-classical monocytes in AH patients were phenotypically distinct to intermediate 240 
monocytes with lower expression of CCR2 (0.2 v 0.8; p<0.001) and CCR5 (0.8 v 1.2; 241 
p<0.05). The percentage of circulating intermediate monocytes was higher and their HLA-242 
DR expression was lower in AH patients who died within 90 days compared to those that 243 
survived (23% v 16% and 18,000 v 37,000 mean fluorescence intensity, respectively; both 244 
p<0.05; Supplementary figure 1B and C). 245 
 246 
Monocyte subsets from AH patients are primed to produce pro-inflammatory cytokines 247 
but refractory to stimulation 248 
High proportions of unstimulated AH monocytes produce pro-inflammatory cytokines and 249 
have greater co-expression of multiple cytokines compared to HV monocytes (Figure 2A). 250 
SPICE analysis showed similar cytokine profiles between unstimulated AH classical and 251 
intermediate monocytes but increased cytokine expression in HV intermediate versus 252 
classical subsets (Figure 2A). Global cytokine expression in AH v HV classical and 253 
intermediate subsets was 85% v 41% (p<0.05) and 89% v 59% (p<0.05) respectively (Figure 254 
2D).  255 
 256 
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Specific cytokine analysis revealed that classical monocytes in AH patients produce higher 257 
levels of IL-6 (37% v 3%; p<0.05), IL-8 (64% v 17%; p<0.05) and IL-23 (11% v 1%; 258 
p<0.05) compared with HVs (Figure 2B).  Intermediate monocytes from AH patients produce 259 
significantly higher levels of IL-1β (72% v 24%; p<0.05), IL-8 (64% v 10%; p<0.05) and IL-260 
23 (11% v 2%; p<0.05) compared with HVs (Figure 2C). HV monocyte subsets have 261 
minimal expression of IL-6, IL-12 and IL-23, but do produce low levels of other pro-262 
inflammatory cytokines (Figure 2B and C).  263 
 264 
Gene expression analysis comparing unstimulated ex vivo AH and HV monocyte subsets 265 
revealed a greater number of differentially expressed genes in intermediate than classical 266 
monocytes (Supplementary figure 2A-C). Increased expression was noted in a range of 267 
chemokines, cytokines and their receptors (Supplementary figure 2B). CCR2 was the second 268 
most differentially expressed gene in AH compared to HV intermediate monocytes after 269 
CLEC4E, a calcium-dependent lectin involved in innate pattern recognition receptor 270 
(Supplementary figure 2B). Consistent with protein analysis, AH intermediate monocytes 271 
expressed higher levels of IL1B and IL8 RNA than HVs. Compared to AH classical 272 
monocytes, AH intermediate monocytes generally expressed greater levels of genes involved 273 
in inflammatory pathways and cell-cell interaction (Supplementary figure 2D-E).  274 
 275 
With regard to monocyte capacity to produce pro-inflammatory cytokines, TLR4 stimulation 276 
with LPS of classical monocytes increased global cytokine expression by 1.4 fold in HVs 277 
compared to no change in AH patients (p<0.05; Figure 2E). This was particularly apparent in 278 
increased expression of both IL-1β and IL-6 compared to AH classical monocytes 279 
(Supplementary Figure 1D). No changes in global cytokine expression were noted in TLR4 280 
stimulated HV or AH intermediate monocytes (Figure 2E). Similar findings were true of 281 
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TLR2/1 (peptidoglygan), TLR3 (PI:C) and TLR 7/8 (R848) stimulation (Supplementary 282 
Table II). AH classical and intermediate monocytes were also unresponsive to endogenous 283 
stimulation with IFNα (Supplementary Table II).  284 
 285 
Monocytes from patients with AH are functionally activated 286 
LPS stimulated phagocytosis of fluorescently labelled microparticles was significantly higher 287 
in both classical and intermediate monocytes from AH patients compared to HV monocytes 288 
(65% v 46% in classical monocytes; p<0.05 and 52% v 19%; p<0.001 in intermediate 289 
monocytes; Figure 3B). In HVs, phagocytic capacity was lower in intermediate compared to 290 
classical monocytes (19% v 46%; p<0.01; Figure 3B). Of monocytes actively phagocytosing 291 
microparticles, intermediate monocytes from AH patients had enhanced ability to 292 
phagocytose more than one particle per monocyte compared to HVs (62% v 36%; p<0.01; 293 
Figure 3C) which was similar to AH classical monocytes (62% v 61%; p>0.05). 294 
 295 
Classical and intermediate monocytes from AH patients drive similar T cell responses 296 
In patients with AH, classical and intermediate monocytes have similar effects on memory 297 
CD4
+
 T cell proliferation and polarization with equal proliferation (65% v 64%; Figure 4A), 298 
IL-17 expression (15.3% v 12.6%; Figure 4B) and IFNγ expression (13.7% v 14.7%; Figure 299 
4C). However, in HVs, intermediate monocytes drove significantly less memory CD4
+
 T cell 300 
proliferation (36% v 46%; p<0.01; Figure 4A) and IL-17 expression (6.5% v 8.6%; p<0.05; 301 
Figure 4B) than classical monocytes and had a higher IFNγ/IL-17 ratio (3.2 v 2.1; p<0.01; 302 
Figure 4E). Compared to HV intermediate monocytes, those from AH patients drove greater 303 
T cell proliferation (64% v 36%; p<0.05; Figure 4A) and IL-17 expression (12.6% v 6.5%; 304 
p<0.05; Figure 4B) with a trend to lower IFNγ expression (4.2% v 18.0%; p=0.09; Figure 305 
4C).  306 
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 307 
Intrahepatic monocytes 308 
Liver tissue from AH patients, taken a median of 7.5 days after clinical diagnosis was made, 309 
demonstrated a significant increase in CD14
+
 monocytes compared to ALD controls (25.7 v 310 
10.5 cells per field; p<0.01; Figure 5B).  This difference was particularly evident in portal 311 
regions in both dual positive CD14
+
CD16
+
 (Figure 5C) and single positive CD14
+
CD16
-
 312 
(Figure 5D) cells versus ALD patients (6.3 v 1.3 cells per field; p<0.05 and 15.7 v 9.0 cells 313 
per field; p<0.05 respectively).  314 
 315 
 316 
  317 
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DISCUSSION 318 
 319 
In this study, we have demonstrated an enrichment of intermediate monocytes in the 320 
peripheral blood of patients with acute severe AH. These are characterized by the 321 
upregulation of CCR2 and expression of pro-inflammatory cytokines. They are also 322 
refractory to TLR stimulation. Furthermore, intermediate monocytes are functionally similar 323 
to classical monocytes in patients with AH. Compared to HVs, both subsets have an activated 324 
phenotype with greater phagocytic capacity, enhanced ability to drive memory T cell 325 
proliferation in co-culture and favor a Th17 phenotype. Liver tissue from AH patients 326 
demonstrates an enrichment of monocytes including the intermediate subset compared to 327 
ALD controls. This leads us to hypothesize that activated circulating monocytes home to the 328 
liver and contribute to disease pathogenesis. 329 
 330 
Severe AH is associated with an enrichment of circulating intermediate monocytes, as 331 
described in other inflammatory diseases (7, 8, 14, 16), which is not a result of either alcohol 332 
related cirrhosis or active heavy alcohol use itself (Figure 1C). Both the percentage of 333 
circulating intermediate monocytes and their activation status (HLA-DR expression) are 334 
associated with clinical outcome (Supplementary figure 1B and C). Protein and gene 335 
expression and functional analyses have enabled characterization of these monocytes in 336 
comparison to HVs. Based on the canonical cell surface markers for classical (CCR2), 337 
intermediate (CCR5) and non-classical monocytes (CX3CR1) (14, 17-19), the elevated 338 
expression of CCR2 in AH intermediate monocytes suggest that they have the ability to 339 
migrate to the inflamed liver, consistent with our liver immunostaining findings. CCL2, the 340 
ligand for CCR2, is highly expressed in AH liver tissue (20). Furthermore, in comparison to 341 
HV intermediate monocytes, CCR5 expression is downregulated in AH intermediate 342 
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monocytes. Reduced CCR5 and elevated CCR2 expression are indicative of an immature 343 
monocyte phenotype (21, 22), suggesting that these monocytes have recently egressed from 344 
the bone marrow as part of the inflammatory response. Other surface proteins involved in 345 
cell-cell interactions were also upregulated including CD80 and CD206, consistent with their 346 
enhanced phagocytosis and proliferative T cell drive (Figures 3 and 4). Furthermore, AH 347 
intermediate monocytes express greater levels of genes involved in inflammatory pathways 348 
and cell-cell interactions compared to classical monocytes suggesting an activated phenotype 349 
(Supplementary figure 2). 350 
 351 
AH monocytes are functionally activated. Intermediate monocytes from AH patients 352 
demonstrated high phagocytic capacity (in both the proportion able to phagocytose and the 353 
number of particles phagocytosed per monocyte; Figure 3). They secreted high levels of pro-354 
inflammatory cytokines but were refractory to further modulation by a range of bacterial, 355 
fungal and viral TLR ligands. Hence, they may already be maximally stimulated in vivo and 356 
cannot further upregulate their intracellular cytokine expression. Importantly, expression of 357 
IL-1β, and IL-23, were higher in classical and intermediate monocytes from patients with AH 358 
compared to HVs (Figure 2). As these cytokines are essential for the differentiation of Th17 359 
cells from naïve CD4
+
 T cells (3, 23), this suggests that these monocytes are skewed to 360 
polarize T cells to a Th17 phenotype in the context of acute inflammation. 361 
 362 
We tested this in vitro and demonstrated that classical rather than intermediate monocytes 363 
from healthy volunteers induce greater memory T cell proliferation and more IL-17 364 
expression with a higher IFNγ:IL-17 ratio. This replicated previous findings (8). However, in 365 
AH patients, in the context of increased expression of IL-1β and IL-23 from their classical 366 
and intermediate monocytes, this was reversed and co-cultured memory T cells had a reduced 367 
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ratio of IFNγ:IL-17 and favored IL-17 expression (Figure 4). This is consistent with previous 368 
reports in patients with alcohol related liver disease (24, 25), but the consequences of this 369 
switch are unclear, as a skew to a Th17 phenotype may either be pro-inflammatory and 370 
pathogenic (26), or control disease through the recruitment of neutrophils which enhance 371 
hepatic regeneration and are associated with an improved prognosis (27, 28). 372 
 373 
Additionally, our data demonstrate an enrichment in intrahepatic monocytes in AH patients 374 
compared to ALD controls (Figure 5) suggesting the acute inflammatory state in AH and not 375 
just heavy alcohol consumption or cirrhosis itself is associated with intrahepatic monocyte 376 
trafficking.  Given the increased expression of liver homing chemokine receptors and the 377 
activated monocyte phenotype of circulating monocytes it is possible that these are the same 378 
cells we have documented within the liver, where they may be contributing to disease 379 
pathogenesis. Further studies are required to examine the dynamics of monocyte liver 380 
infiltration. 381 
 382 
We have compared our findings in patients with AH to healthy controls as well as ALD 383 
patients. The latter group were selected as appropriate disease controls as they shared many 384 
clinical characteristics with AH patients (ongoing alcohol consumption, demographics, 385 
underlying liver disease and were hospitalizsed). This has allowed us to conclude that the 386 
differences seen in AH patients were not simply due to alcohol consumption or underlying 387 
liver disease but related to the inflammatory state of AH. 388 
 389 
There remains debate over the functional phenotype of the intermediate monocyte (29) with 390 
observations of similarities to both the classical (30) and non-classical (18) subsets. Some 391 
studies have reported that intermediate monocytes are the main producers of pro-392 
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inflammatory cytokines (30) while others that they are anti-inflammatory with high 393 
expression of IL-10 in response to TLR4 ligand (31). What is clear is that there is significant 394 
heterogeneity of monocytes, which has been well defined in the healthy state (18, 19, 32, 33). 395 
Recent single-cell RNA sequencing has further categorized CD16
+
 monocytes into three 396 
distinct subsets with some functional overlap with classical and non-classical monocytes (34). 397 
Although the expansion of intermediate monocytes has been reported in several inflammatory 398 
conditions and proposed as a biomarker of outcome (35), there are few reports of their 399 
function in inflammatory states. Consistent with our findings, the best data are from patients 400 
with rheumatoid arthritis in which intermediate monocytes induced IL-17 expression from 401 
CD4
+
 T cells (36). However, further functional phenotyping has not been conducted.  402 
 403 
Here were present the first report of the functional phenotype of intermediate monocytes in 404 
AH. We conclude that, in AH, intermediate monocytes are functionally activated. The 405 
intermediate monocyte subset is expanded in the peripheral circulation, tracks to the site of 406 
inflammation and has increased phagocytic capacity and ability to drive both T cell 407 
proliferation and IL-17 expression than in normal homeostatic conditions. In this acute 408 
inflammatory condition, intermediate monocytes may play a role in disease pathogenesis and, 409 
therefore, are candidates for further study in the development of disease-specific biomarkers 410 
and targeted immune therapies.  411 
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FIGURE LEGENDS 549 
 550 
Figure 1. Intermediate monocytes are enriched in patients with AH and have an altered 551 
phenotype compared to HVs. (A) Absolute monocyte counts at baseline of treatment with 552 
glucocorticoids in 41 patients with AH (mean and SD). Normal range for the local population 553 
is shown (dashed lines). (B) Representative FACS dotplot of CD14 and CD16 expression on 554 
monocytes in a HV and a patient with AH. (C) Monocyte subsets as a percentage of total 555 
monocyte numbers in HVs (n=47), patients with AH at initial presentation (n=41) and ALD 556 
patients (n=10) for classical, intermediate and non-classical subsets. Scatter dot plots show 557 
mean and SEM. (D) CCR2, CCR5, CX3CR1, HLA-DR, CD206 and CD80 surface protein 558 
expression in monocyte subsets in HVs (n=14) and patients with AH (n=14) was quantified 559 
by flow cytometry. Mean fluorescence intensity was normalized to HV classical monocyte 560 
expression of each marker and expressed as a fold difference. Bars charts show mean with 561 
SEM. *p<0.05; **p<0.01; ***p<0.001. 562 
 563 
Figure 2. Monocytes from patients with AH express higher levels of pro-inflammatory 564 
cytokines than healthy volunteers. Classical and intermediate monocyte subsets from HVs 565 
(n=3) and patients with AH (n=5) were sorted by flow cytometry and cultured for 18-24h 566 
with or without LPS stimulation before intracellular cytokine expression was measured by 567 
flow cytometry. (A) Simplified Presentation of Incredibly Complex Evaluations (SPICE) 568 
analysis of intracellular cytokines demonstrates greater cytokine expression and co-569 
expression of multiple cytokines in both classical and intermediate monocytes from AH 570 
patients versus HVs. (B) and (C) Unstimulated individual cytokine expression in classical (B) 571 
and intermediate (C) monocytes in HVs and patients with AH. (D) Global cytokine 572 
expression (total percentage positive for any cytokine) in classical and intermediate 573 
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monocytes in HVs and patients with AH. Unstimulated classical and intermediate monocytes 574 
secrete more cytokines from AH patients than HVs (85% v 41%; p<0.05 and 89% v 59%; 575 
p<0.05 respectively). (E) Fold change in global cytokine expression in the presence of LPS. 576 
Addition of LPS does not yield any difference in cytokine expression AH monocyte subsets 577 
or in HV intermediate monocytes. Bars charts show mean with SEM. 578 
 579 
Figure 3. AH monocytes have enhanced phagocytic capacity compared to HV 580 
monocytes. Monocytes isolated by magnetic bead separation from HVs (n=5) and patients 581 
with AH (n=10) were cultured with fluorescent coated microspheres in the presence of LPS. 582 
(A) Example flow cytometry dotplot of monocyte subsets cultured with fluorescent 583 
microparticles. Histograms demonstrate monocytes positive and negative for fluorescently 584 
labelled microparticles from classical and intermediate monocyte subsets. Intensity of 585 
fluorescence represents the number of microparticles phagocytosed by each monocyte. (B) 586 
The proportion of monocytes with intracellular microparticles was quantified in each 587 
monocyte subset by flow cytometry. Monocytes from AH patients were more efficient at 588 
phagocytosis compared to those from HVs. (C) The proportion of monocytes from each 589 
subset which had phagocytosed 2 or more microparticles each was quantified in monocytes 590 
from HVs and patients with AH. Intermediate monocytes from AH patients had greater 591 
capacity to phagocytose more than 1 microparticle each compared to those from HVs. Scatter 592 
dot plots show mean and SEM. *p<0.05; **p<0.01; ***p<0.001.  593 
 594 
Figure 4. Monocytes from AH patients drive greater T cell proliferation and IL-17A 595 
expression than HV monocytes. Memory T cells and monocyte subsets were isolated from 596 
HVs (n=16) and patients with AH (n=5) and co-cultured. T cells were labelled with CFSE 597 
and proliferation was determined by CFSE dilution and intracellular cytokine expression 598 
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determined by flow cytometry. (A) Percentage of CFSE
lo
 memory T cells. (B) and (C). 599 
Percentage of single positive IL-17 (B) and IFNγ (C) expressing cells. (D) Percentage of cells 600 
co-expressing IL-17 and IFNγ. (E) Ratio of IFNγ/IL-17. Bars charts show mean with SEM. 601 
*p<0.05; **p<0.01 602 
 603 
Figure 5. Intrahepatic monocytes are enriched in patients with AH. (A) Representative 604 
confocal immunostaining images from the portal tract of a liver biopsy from a patient with 605 
AH (left) and ALD control (right) with multiple dual staining cells (yellow) seen in the AH 606 
sample only. ALD controls are actively drinking patients with cirrhosi  but no acute 607 
inflammatory component. (B) The mean number of CD14
+
 monocytes in liver tissue from 608 
patients with AH (n=7) and patients with ALD (n=4) taken a median of 7.5 days after 609 
commencement of glucocorticoid treatment averaged from 3 portal and 3 lobular fields. (C) 610 
There are more CD14
+
CD16
+
 monocytes in portal areas in AH compared to ALD patients 611 
(6.3 v 1.3; p<0.05). (D) There are more CD14
+
CD16
-
 monocytes in portal regions in AH 612 
compared to ALD patients (15.7 v 9.0; p<0.05). Scatter dot plots show mean with SEM. 613 
*p<0.05. 614 
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Table 1. Participant characteristics for AH and ALD patients at baseline and mortality at 
days 28 and 90. 
  Disease category 
  AH (n=41) ALD (n=10) 
Age 50.2 (13.4) 51.8 (9.8) 
Gender (%female) 52 50 
Bilirubin (µmol/L) 288 (166) 102 (73) 
Albumin (g/L) 25.7 (7.1) 30.1 (5.1) 
INR 1.6 (0.5) 1.6 (0.5) 
Creatinine (µmol/L) 68.4 (40.1) 70.1 (20.0) 
Sodium (µmol/L) 133 (53) 128.3 (9.7) 
DF 60.8 (23.9) 28.1 (28.4) 
MELD 18.1 (6.6) 15.1 (5.4) 
28 day mortality (%) 14 10 
90 day mortality (%) 24 30 
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